Expression levels of chemokine (C-X-C motif) ligands CXCL1 and CXCL3 as prognostic biomarkers in rectal adenocarcinoma: evidence from Gene Expression Omnibus (GEO) analyses

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Goding Sauer A, et al. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70(3):145–164.
   PubMed Web of Science ®Google Scholar
• Barabasi AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12(1):56–68.
   PubMed Web of Science ®Google Scholar
• Conte F, Fiscon G, Licursi V, et al. A paradigm shift in medicine: a comprehensive review of network-based approaches. Biochim Biophys Acta Gene Regul Mech. 2020;1863(6):194416.
   PubMed Web of Science ®Google Scholar
• Paci P, Fiscon G, Conte F, et al. Gene co-expression in the interactome: moving from correlation toward causation via an integrated approach to disease module discovery. NPJ Syst Biol Appl. 2021;7(1):3.
   PubMed Web of Science ®Google Scholar
• Falcone R, Conte F, Fiscon G, et al. BRAF(V600E)-mutant cancers display a variety of networks by SWIM analysis: prediction of vemurafenib clinical response. Endocrine. 2019;64(2):406–413.
   PubMed Web of Science ®Google Scholar
• Grimaldi AM, Conte F, Pane K, et al. The new paradigm of network medicine to analyze breast cancer phenotypes. Int J Mol Sci. 2020;21:18.
   Web of Science ®Google Scholar
• Panebianco V, Pecoraro M, Fiscon G, et al. Prostate cancer screening research can benefit from network medicine: an emerging awareness. NPJ Syst Biol Appl. 2020;6(1):13.
   PubMed Web of Science ®Google Scholar
• Zhang B, Wang J, Wang X, et al. Proteogenomic characterization of human colon and rectal cancer. Nature. 2014;513(7518):382–387.
   PubMed Web of Science ®Google Scholar
• Ganesh K, Wu C, O’Rourke KP, et al. A rectal cancer organoid platform to study individual responses to chemoradiation. Nat Med. 2019;25(10):1607–1614.
   PubMed Web of Science ®Google Scholar
• Nagasaki T, Akiyoshi T, Fujimoto Y, et al. Prognostic impact of neutrophil-to-lymphocyte ratio in patients with advanced low rectal cancer treated with preoperative chemoradiotherapy. Dig Surg. 2015;32(6):496–503.
   PubMed Web of Science ®Google Scholar
• Portale G, Cavallin F, Valdegamberi A, et al. Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio are not prognostic biomarkers in rectal cancer patients with curative resection. J Gastrointest Surg. 2018;22(9):1611–1618.
   PubMed Web of Science ®Google Scholar
• Dudani S, Marginean H, Tang PA, et al. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation. BMC Cancer. 2019;19(1):664.
   PubMedGoogle Scholar
• Avoranta ST, Korkeila EA, Ristamaki RH, et al. ALDH1 expression indicates chemotherapy resistance and poor outcome in node-negative rectal cancer. Hum Pathol. 2013;44(6):966–974.
   PubMed Web of Science ®Google Scholar
• Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013;41( Database issue):D991–5.
   PubMed Web of Science ®Google Scholar
• Licursi V, Conte F, Fiscon G, et al. MIENTURNET: an interactive web tool for microRNA-target enrichment and network-based analysis. BMC Bioinformatics. 2019;20(1):545.
   PubMed Web of Science ®Google Scholar
• Huang Da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–D13.
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504.
   PubMed Web of Science ®Google Scholar
• Chin CH, Chen SH, Wu HH, et al. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(Suppl 4):S11.
   PubMed Web of Science ®Google Scholar
• Goldman MJ, Craft B, Hastie M, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675–678.
   PubMed Web of Science ®Google Scholar
• Rhodes D, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (New York, NY) 2004;6(1):1–6.
   PubMed Web of Science ®Google Scholar
• Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102.
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e10.
   PubMed Web of Science ®Google Scholar
• Jiao D, Chen J, Li Y, et al. miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT. J Cell Mol Med. 2018;22(7):3526–3536.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang L, Mao S, et al. miR-1-3p contributes to cell proliferation and invasion by targeting glutaminase in bladder cancer cells. Cell Physiol Biochem. 2018;51(2):513–527.
   PubMedGoogle Scholar
• Ke J, Zhang B, Li Y, et al. MiR-1-3p suppresses cell proliferation and invasion and targets STC2 in gastric cancer. Eur Rev Med Pharmacol Sci. 2019;23(20):8870–8877.
   PubMed Web of Science ®Google Scholar
• Wang N, Liu W, Zheng Y, et al. CXCL1 derived from tumor-associated macrophages promotes breast cancer metastasis via activating NF-kappaB/SOX4 signaling. Cell Death Dis. 2018;9(9):880.
   PubMed Web of Science ®Google Scholar
• Miyake M, Hori S, Morizawa Y, et al. CXCL1-mediated interaction of cancer cells with tumor-associated macrophages and cancer-associated fibroblasts promotes tumor progression in human bladder cancer. Neoplasia. 2016;18(10):636–646.
   PubMed Web of Science ®Google Scholar
• Sun X, He X, Zhang Y, et al. Inflammatory cell-derived CXCL3 promotes pancreatic cancer metastasis through a novel myofibroblast-hijacked cancer escape mechanism. Gut 2021.
   Web of Science ®Google Scholar
• Zhang Z, Chen Y, Jiang Y, et al. Prognostic and clinicopathological significance of CXCL1 in cancers: a systematic review and meta-analysis. Cancer Biol Ther. 2019;20(11):1380–1388.
   PubMed Web of Science ®Google Scholar
• Chen T, Du D, Chen J, et al. ZC3H12A expression in different stages of colorectal cancer. Oncoscience 2019;6:301–311.
   PubMedGoogle Scholar
• Yang C, Yu H, Chen R, et al. CXCL1 stimulates migration and invasion in ERnegative breast cancer cells via activation of the ERK/MMP2/9 signaling axis. Int J Oncol. 2019;55(3):684–696.
   PubMed Web of Science ®Google Scholar
• Liu ZY, Zheng M, Li YM, et al. RIP3 promotes colitis-associated colorectal cancer by controlling tumor cell proliferation and CXCL1-induced immune suppression. Theranostics. 2019;9(12):3659–3673.
   PubMed Web of Science ®Google Scholar
• Acharyya S, Oskarsson T, Vanharanta S, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell. 2012;150(1):165–178.
   PubMed Web of Science ®Google Scholar
• Wen Z, Liu Q, Wu J, et al. Fibroblast activation protein alpha-positive pancreatic stellate cells promote the migration and invasion of pancreatic cancer by CXCL1-mediated Akt phosphorylation. Ann Transl Med. 2019;7(20):532.
   PubMed Web of Science ®Google Scholar
• Casasanta MA, Yoo CC, Udayasuryan B, et al. Fusobacterium nucleatum host-cell binding and invasion induces IL-8 and CXCL1 secretion that drives colorectal cancer cell migration. Sci Signal. 2020;13:641.
   Web of Science ®Google Scholar
• Han KQ, Han H, He XQ, et al. Chemokine CXCL1 may serve as a potential molecular target for hepatocellular carcinoma. Cancer Med. 2016;5(10):2861–2871.
   PubMed Web of Science ®Google Scholar
• Wei LY, Lee JJ, Yeh CY, et al. Reciprocal activation of cancer-associated fibroblasts and oral squamous carcinoma cells through CXCL1. Oral Oncol. 2019;88:115–123.
   PubMed Web of Science ®Google Scholar
• Cabrero-de Las Heras S, Martinez-Balibrea E. CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer. World J Gastroenterol. 2018;24(42):4738–4749.
   PubMed Web of Science ®Google Scholar
• Salama AAA, Allam RM. Promising targets of chrysin and daidzein in colorectal cancer: amphiregulin, CXCL1, and MMP-9. Eur J Pharmacol. 2021 Feb 5;892:173763.
   Google Scholar
• Ogawa R, Yamamoto T, Hirai H, et al. Loss of SMAD4 promotes colorectal cancer progression by recruiting tumor-associated neutrophils via the CXCL1/8-CXCR2 axis. Clin Cancer Res. 2019;25(9):2887–2899.
   PubMed Web of Science ®Google Scholar
• Zhang H, Ye YL, Li MX, et al. CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer. Oncogene. 2017;36(15):2095–2104.
   PubMed Web of Science ®Google Scholar
• Chen MC, Baskaran R, Lee NH, et al. CXCL2/CXCR2 axis induces cancer stem cell characteristics in CPT-11-resistant LoVo colon cancer cells via Galphai-2 and Galphaq/11. J Cell Physiol. 2019;234(7):11822–11834.
   PubMed Web of Science ®Google Scholar
• Subat S, Mogushi K, Yasen M, et al. Identification of genes and pathways, including the CXCL2 axis, altered by DNA methylation in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2019;145(3):675–684.
   PubMed Web of Science ®Google Scholar
• Ding J, Xu K, Zhang J, et al. Overexpression of CXCL2 inhibits cell proliferation and promotes apoptosis in hepatocellular carcinoma. BMB Rep. 2018;51(12):630–635.
   PubMed Web of Science ®Google Scholar
• Liao W, Overman MJ, Boutin AT, et al. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell. 2019;35(4):559–72.e7.
   PubMed Web of Science ®Google Scholar
• Ruan GT, Gong YZ, Liao XW, et al. Diagnostic and prognostic values of CXC motif chemokine ligand 3 in patients with colon cancer. Oncol Rep. 2019;42(5):1996–2008.
   PubMed Web of Science ®Google Scholar
• Wei CY, Zhu MX, Lu NH, et al. Circular RNA circ_0020710 drives tumor progression and immune evasion by regulating the miR-370-3p/CXCL12 axis in melanoma. Mol Cancer. 2020;19(1):84.
   PubMed Web of Science ®Google Scholar
• Zhu D, Gu X, Lin Z, et al. High expression of PSMC2 promotes gallbladder cancer through regulation of GNG4 and predicts poor prognosis. Oncogenesis. 2021;10(5):43.
   PubMed Web of Science ®Google Scholar
• Takehara M, Sato Y, Kimura T, et al. Cancer-associated adipocytes promote pancreatic cancer progression through SAA1 expression. Cancer Sci. 2020;111(8):2883–2894.
   PubMed Web of Science ®Google Scholar
• Wang G, Zhou Y, Yu Z, et al. Up-regulated ONECUT2 and down-regulated SST promote gastric cell migration, invasion, epithelial-mesenchymal transition and tumor growth in gastric cancer. Eur Rev Med Pharmacol Sci. 2020;24(18):9378–9390.
   PubMed Web of Science ®Google Scholar
• Misawa K, Mochizuki D, Endo S, et al. Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: potential utility as biomarkers for prognosis. Mol Carcinog. 2017;56(3):1107–1116.
   PubMed Web of Science ®Google Scholar